Form 4: Lifecore Biomedical Director Nelson Obus Acquires 19,506 Restricted Stock Units

Lifecore Biomedical, Inc. Director Nelson Obus acquired 19,506 restricted stock units, increasing his direct beneficial ownership to 138,193 shares.

Summary

• Director Nelson Obus of Lifecore Biomedical, Inc. acquired 19,506 restricted stock units (RSUs).
• The transaction date for this acquisition was July 15, 2025.
• These RSUs convert into common stock on a 1-for-1 basis.
• The RSUs will vest on the earlier of July 15, 2026 (one-year anniversary of the grant date) or the date of the company's first annual meeting of stockholders in calendar year 2026, provided that date is no less than 50 weeks from the grant date.
• Following this transaction, Nelson Obus directly beneficially owns 138,193 shares of Lifecore Biomedical, Inc. common stock.

Sentiment

Score: 8

Explanation: The acquisition of restricted stock units by a director is a strong positive signal, indicating insider confidence and aligning management incentives with shareholder interests. This type of transaction is generally well-received by the market.

Positives

• The acquisition of 19,506 restricted stock units by a director indicates a positive signal of confidence in the company's future performance and aligns management's interests with shareholders.
• The increase in direct beneficial ownership to 138,193 shares by a director strengthens insider commitment.

Future Outlook

The vesting schedule for the acquired restricted stock units indicates a future commitment by the director, aligning their interests with the company's long-term performance through at least mid-2026.

Industry Context

This transaction is a routine insider filing, common across all industries, where directors receive equity compensation or acquire shares, signaling their belief in the company's prospects within its specific sector.

Related Party Transactions

• The acquisition of 19,506 restricted stock units by Director Nelson Obus is a related party transaction, as it involves an insider of Lifecore Biomedical, Inc.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director can be seen as a positive signal, potentially increasing investor confidence and aligning director interests with shareholder returns.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The restricted stock units are expected to vest on the earlier of July 15, 2026, or the date of the company's first annual meeting of stockholders in calendar year 2026 (subject to a 50-week minimum from grant date).

Key Dates

Recommendation

Keywords

Lifecore Biomedical, LFCR, Nelson Obus, Restricted Stock Units, RSU, Insider Trading, Director Ownership, SEC Form 4, Equity Compensation, Stock Vesting